Second Genome Inc.
Personalizing medicine by better understanding bacteria
This article was originally published in Start Up
Second Genome Inc. intends to leverage new understandings arising from research into the human microbiome about how microorganisms influence human disease and health. The start-up anticipates that its microbiome discovery platform will expose many possibilities for diagnosis and treatment of disease not previously connected with bacteria. Initially the start-up is intent on establishing that its methods can classify patients with irritable bowel syndrome and guide their treatment.
You may also be interested in...
The French firm has partners for its diagnostics, wants to spin out a "stool banking" company, and might follow other microbiome start-ups into drug discovery to explore the connections between our bugs and our immune system.
Second Genome’s ulcerative colitis research alliance with Janssen Biotech is a first in the burgeoning microbiome therapeutics space, which may be transitioning from venture investment to commercial partnering. But is the deal an inflection point or a fluke?
Financings Of The Fortnight Sees New Biotech Funding All Over The Globe, And Without Much VC Participation
Plus news on recent financial activity by Merrimack, Promethera, ADC Therapeutics and Enterome Bioscience.